Nervous Disorder TRIZ Cases

Dual GABA receptor modulation via allosteric modulators and gaboxadol treats refractory status epilepticus while reducing psychiatric adverse events.

A high shear device mixes therapeutic gases with liquid carriers to produce nanobubbles under 1.5 micrometers.

Agonist and antagonist antibodies bind TREM2 and DAP12 receptors to regulate immune cell functions.

Detecting autoantibodies binding to the alpha 3 subunit of neuronal Na+/K+ ATPase in bodily fluids enables specific biomarker identification.

Humanized antibodies inhibit P-selectin-mediated adhesion, resolving the trade-off between therapeutic efficacy and increased immune response.

Placental stem cells reduce chronic and neuropathic pain resistant to conventional therapies by modulating immune responses.

Replacing sulforaphane nitrile groups with stable isothiocyanates extends Nrf2 activation duration while reducing cytotoxicity.

Diaryl and arylheteroaryl urea derivatives act as 5-HT2A inverse agonists to manage neuropsychiatric symptoms.

Hydroxyl-terminated polyester compositions conjugate bioactive peptides to balance bonding strength and flexural modulus for safe tissue adhesion.

Lentiviral vectors deliver transgenes to hematopoietic stem cells, reversing tumor immunosuppression and enhancing anti-tumor immunity.

AAV9 vector delivers GAD65 and VGAT genes to spinal neurons, avoiding systemic sedation.

Antigen-binding proteins target human GM-CSF to block receptor interaction and inhibit myeloid cell proliferation.

A method establishes progenitor cell lines by selecting for self-renewal capacity in embryonic stem cultures without feeder cells.

Replacing 8-MOP with porphyrin derivatives eliminates carcinogenic risks from non-selective UV-A exposure while maintaining effective lymphocyte destruction.

Engineered AAV capsid proteins with specific amino acid substitutions enable selective transduction of neuronal and cardiac tissues.

Polyvinyl alcohol resin mixed with maltose creates an extensible coating that prevents cracking under high humidity while maintaining rapid disintegration.

An adhesive matrix solubilizes memantine salt via specific counteranions to prevent dose dumping and maintain therapeutic blood concentrations.

Nypa fruticans Wurmb extract inhibits TRPV1 channels to alleviate neuropathic pain without the toxicity of conventional opioids.

External stimuli trigger liposome rupture to release local anesthetics, resolving the trade-off between prolonged duration and adjustable timing.

Replaces foreign animal serum with screened human serum and removes heparin to prevent contamination while maintaining high cell proliferation rates.

Cyclized D-amino acid peptides overcome insufficient binding stability of linear analogs to prevent toxic oligomer formation and support early detection.

Thiophene compounds inhibit branched-chain ketoacid dehydrogenase kinase to reduce elevated amino acid levels in metabolic disorders.

Targeted OGA inhibitors penetrate the blood-brain barrier to prevent tau hyperphosphorylation and aggregation, addressing underlying Alzheimer's pathology.

Novel S1P and ATX modulating compounds target specific biological pathways to address demyelination disorders.

A prenatal probiotic composition establishes a gut microbiome colony to reduce autism spectrum disorder symptoms.

Combining baclofen and chlorzoxazone modulates potassium channels to improve Purkinje neuron function in cerebellar ataxia.

Binding agents extract toxic amyloid-beta oligomers from blood and organs, preventing disease transmission during transfusions.

Converting hippocampal glial cells into GABAergic neurons via NeuroD1 delivery reduces seizures and rescues cognitive deficits.

CRISPR/Cas9 guide RNAs delete mutant huntingtin alleles, eliminating residual protein that limits RNA interference efficacy.

Recombinant adeno-associated virus vectors deliver miR-122 inhibitors to hepatocytes for sustained lipid modulation.

Dynamic HARQ process ID reuse recovers reserved identifiers after successful semi-persistent transmissions, resolving resource wastage in wireless systems.

Engineered chimeric receptors fuse mutated ligand binding domains with transmembrane channels to achieve selective neuronal activation.

Segmented dosing and periodic action principles stabilize serotonin concentrations, reducing gastrointestinal side effects while improving patient compliance.

Substituted imidazo[2,1-f][1,2,4]triazine compounds selectively inhibit PI3K-gamma enzyme activity.

Platelet tropomyosin isoform detection replaces post-mortem analysis, enabling early Alzheimer's diagnosis with high sensitivity.

A carbamate compound prevents acute stress disorder symptoms through noradrenaline reuptake inhibition.

Soluble Toll-like receptor compounds bind and neutralize disease-associated molecular patterns to reduce neurodegenerative toxicity.

Heteroaryl compounds overcome NSCLC treatment resistance by selectively inhibiting mutant EGFR exon 20 insertion mutations.

Expressing exogenous NeuroD1 in reactive astrocytes converts scar tissue into functional neurons, bypassing the central nervous system regeneration barrier.

Ester-modified capsaicinoid prodrugs deliver sustained analgesia by controlling hydrolysis rates, eliminating opioid addiction risks.

Tau-binding antibodies target phosphorylated Tau epitopes to neutralize toxic species, addressing the lack of disease-modifying therapies for tauopathies.

Composite immunogens combine amyloid-beta, tau, and alpha-synuclein B cell epitopes with universal T helper regions to stimulate targeted antibody production.

A glycine and amino acid composition restores mitochondrial respiration to support cellular energy metabolism.

Centrifugation and filtration concentrate arylsulfatase A to 25 mg/ml while keeping aggregates below 5 w/w% to prevent immune responses.

Compounds of formula I disrupt sortilin and pro-neurotrophin interactions, reducing apoptosis and inflammation in neurodegenerative disorders.

NSI-189 treats depression in patients with impaired memory and specific EEG patterns, resolving trial-and-error medication selection.

Segmented glycyl-tRNA synthetase polypeptides modulate cellular proliferation and apoptosis through targeted domain isolation.

A liquid antibody preparation uses a viscosity inhibitor to maintain low viscosity at high concentrations.